Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male, aged 12 to 65 years~* Severe hemophilia A~* History of more than 150 exposure days (ED) with clotting factor concentrates~* Currently receiving episodic treatment with FVIII; no regular prophylaxis for more than 6 consecutive months in the past 5 years~* No current Factor VIII inhibitor or history of inhibitor~* Willing to use electronic patient diary~Exclusion Criteria:~* Presence of another bleeding disease that is different from hemophilia A~* Thrombocytopenia~* Abnormal renal function~* Presence of active liver disease~* Known hypersensitivity to FVIII

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: rFVIII on demand first CS/EP then CS/ADJ (Type: EXPERIMENTAL): Participants received on-demand treatment with recombinant factor VIII (rFVIII, BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months, followed by cross-over to study drug assayed by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months.
- Arm 2: rFVIII on demand first CS/ADJ then CS/EP (Type: EXPERIMENTAL): Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/ADJ for 6 months, followed by cross-over to study drug assayed by CS/EP for 6 months.
- Arm 3: rFVIII prophylaxis low-dose first CS/EP then CS/ADJ (Type: EXPERIMENTAL): Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII(BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
- Arm 4: rFVIII prophylaxis low-dose first CS/ADJ then CS/EP (Type: EXPERIMENTAL): Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
- Arm 5: rFVIII prophylaxis high-dose first CS/EP then CS/ADJ (Type: EXPERIMENTAL): Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
- Arm 6: rFVIII prophylaxis high-dose first CS/ADJ then CS/EP (Type: EXPERIMENTAL): Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII(BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).